Of course, one of the news that has most shocked the Ibex 35 is the departure of several companies in their natural setting, such as Catalonia. Some are as relevant as Banco Sabadell, Caixabank or Gas Natural. As a consequence of these exceptional decisions, only one listed company remains in this important geographical area. It is none other than the pharmaceutical company Grifols that continues to be listed in the selective stock market index without changing your strategy regarding its establishment at the corporate headquarters. In this sense, one of the concerns of investors is whether this measure will benefit them or on the contrary it will take its toll on the equity markets.
Grifols is a company listed on the stock index IBEX 35 since 2008 and also on the Nasdaq since 2011. Of all the companies in the selective index of Spanish equities that are framed within the Catalan sphere of action, it is the only one that has not moved its headquarters outside of Catalonia due to the crisis caused by the independence process. To the point that it has not modified its operations and maintains the same business constants as always.
Grifols is being one of the most stable values of the national equities. With a completely immaculate evolution in the financial markets, although they are slight corrections in their prices. To the point of having become one of the preferred options for small and medium investors. Nevertheless, an unexplored path now opens that no one, or at least very few, know where it can actually lead. Beyond spikes or specific depreciations in its price.
Grifols: how is your situation?
Is an incognito that is waiting to be solved so that shareholders can make a decision. On whether it is convenient to continue in open positions. Or if, on the contrary, it is more advisable to close positions in this company that is listed on the Ibex 35. On the other hand, it will also be very important information for investors who are out of value. So that they can know what is the most appropriate strategy for these precise moments. Whether to take positions from now on or it will be better to wait a few months to return to the equity sector through this proposal from the Spanish stock market.
Regarding its income statement, it should be noted that the Catalan multinational of blood products has registered a net profit of 277,9 million euros in the first half of 2017. These data indicate that there is an increase of 5,1% compared to the same period of the previous year. In this sense, this figure represents 12,7% of the company's income, which from January to June stood at 2.192,4 million euros.
Sponsor the Camp Nou
Either way, there is a very relevant piece of news that is close to the intentions of the Catalan company. It is an agreement with the Barcelona Football Club so that the Nou Camp stadium is renamed Camp Nou Grífols soon. The agreement could report to the "culés" about 400 million dollars in a period of 30 years as a result of this commercial agreement between the two entities. Although the news is still unconfirmed, both by the Blaugranas and Grifols.
In this way, its presence on the Catalan scene would be practically assured for the next few years. Unlike the other companies that are listed on the Spanish selective index. Not surprisingly, they have opted for completely different strategies. In this sense, it is very interesting how these listed companies can evolve, at least until the end of this year. So that one way or another send a message to small and medium investors on its situation in the national markets. So which strategy is more to the taste of retailers.
Grifols is trading at 25 euros
The current quotation of their prices is very close to the levels of 25 euros. With a revaluation that is very close to 30%. Being, in any case, one of the national selective index values with the best performance during the first ten months of the year. Very close to reaching the almost 27 euros at which it traded this past summer. To the point that this level of quotation has become one of the main resistances that it faces. Especially if your aspirations are to reach 30 euros per share in the coming months. Which is one of the objectives set out in the operations carried out from now on.
At this time it remains one of the most recommended equity proposals by financial analysts. Although with the logical doubts that a value that has risen a lot in recent years. To the point that a serious correction in their prices is not ruled out. In this sense, caution should be the common denominator in the operations of small and medium investors. Because the falls could be of great severity if there is a change in trend from now on. Only if overcome resistance at 27 euros it could be considered as an optimal entry level to make the savings profitable with all possible guarantees.
Dividend distribution in the company
On the other hand, the distribution of dividends among shareholders is also interesting. In this sense, Grifols has decided to allocate 218 million euros to this remuneration charged to the results of this year. With a 17% annual growth in the last four years. With an account that has already been paid last December of 0,18 euros gross per share and a second charge of 0,13 euros that has been made last summer. Being, in any case, one of the incentives to take positions in this important value of the Ibex 35. So that you can have a guaranteed return on your savings every year.
From this perspective, it provides greater stability to the investment portfolio of savers. Due to the fact that many years they focus their positions on longer terms of stay. Without having to resort to operations of a more speculative nature. A factor that undoubtedly adds more security to the evolution of your prices. Where volatility is not as pronounced as in other values of Spanish equities. Through some fluctuations in their prices that are not especially striking.
Excessive exposure to the dollar
However, one of the problems posed by its operations is its great dependence on the currency of the United States. From this perspective, it cannot be forgotten at any time that the Catalan pharmaceutical company has been particularly affected by its exposure to the United States health market. To the point that some periods of the year their shares have depreciated very notably. One of the most important data is that derived from the fact that the Catalan company invoices almost 61% of its income in the United States.
In this sense, their interrelation is more than remarkable and it is one of the most important factors that may give some or other signal about their possible falls or revaluations. Above other technical or fundamental approaches. Pay special attention to all the news that has these parameters as a point of reference. They will largely determine its evolution in the coming months and up to years. Both in one sense or another and as a complement to other entry and exit signals in financial markets.
Open to all profiles
In any case, you are looking at one of the Spanish equity securities with a short history. Not surprisingly, it has been trading on the financial markets in a relatively short time. With a very positive evolution and that has surprised more than one analyst. First-time investors have been able to build a savings bag certainly relevant until reaching the current levels in their prices. Forming part of many of the portfolios that have been developed by the most important managers in capital funds in much of the financial world. So that they can be subscribed by all the profiles in the users. From what they look for more aggressive approaches to the eminently defensive ones. No exclusions with respect to its recipients.
One of its main characteristics is that its actions will not generate excessive problems for you. The risks will not be higher than in other securities on the Spanish stock market. And this is something to welcome in the worst of times for equity markets. Not surprisingly, it has a very stable shareholding that provides greater security to its listing. But without being exempt from offering you great joys because it is a line of business that works very well in many of the countries where they market their products.